KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBITDA Margin (2016 - 2025)

Pacira BioSciences has reported EBITDA Margin over the past 16 years, most recently at 1.19% for Q4 2025.

  • Quarterly results put EBITDA Margin at 1.19% for Q4 2025, down 1200.0% from a year ago — trailing twelve months through Dec 2025 was 2.64% (up 1311.0% YoY), and the annual figure for FY2025 was 2.64%, up 1311.0%.
  • EBITDA Margin for Q4 2025 was 1.19% at Pacira BioSciences, down from 3.54% in the prior quarter.
  • Over the last five years, EBITDA Margin for PCRX hit a ceiling of 25.7% in Q2 2021 and a floor of 82.77% in Q3 2024.
  • Median EBITDA Margin over the past 5 years was 10.91% (2022), compared with a mean of 6.45%.
  • Biggest five-year swings in EBITDA Margin: crashed -9358bps in 2024 and later skyrocketed 8631bps in 2025.
  • Pacira BioSciences' EBITDA Margin stood at 2.65% in 2021, then decreased by -24bps to 2.01% in 2022, then soared by 810bps to 18.3% in 2023, then dropped by -28bps to 13.19% in 2024, then crashed by -91bps to 1.19% in 2025.
  • The last three reported values for EBITDA Margin were 1.19% (Q4 2025), 3.54% (Q3 2025), and 4.69% (Q2 2025) per Business Quant data.